Boston Scientific Warns On Earnings After Cyberattack
Boston Scientific (BSX) warned it may miss Q3 and full-year earnings and sales targets due to a cyberattack in late August, with full-year EPS guidance previously set at $3.28-$3.32 and sales growth at 5.5%-6.5%. The company will provide an update on October 28. BSX stock has fallen 50% this year.
How this was made
The 30-second read
Why it matters
The guidance miss is material for investors and may trigger sell‑offs, especially ahead of the upcoming earnings call on Oct. 28.
Market read
BSX guidance miss is a significant event for the med‑tech sector and could influence related stocks.
What to watch
Potential insurance recoveries or cost‑saving measures not yet disclosed could mitigate the downside.
Background
Boston Scientific disclosed a cyberattack on Aug. 25 that disrupted operations and now warns it will likely miss its guidance.
Ticker impact
Boston Scientific warned it will likely miss its Q3 and full-year net sales growth and EPS guidance after a cyberattack.
Downward pressure on BSX price in the near term.
Guidance is a primary driver for valuation; a miss after a cyber incident adds operational risk.
Market effects
Medical device sector may see heightened scrutiny of cyber resilience, potentially affecting peers.
U.S. healthcare stocks could face short-term volatility.
Limited to U.S. listed med‑tech firms; no broad macro effect.
Counterpoint
If the cyberattack impact is contained, the guidance miss may be overblown, presenting a buying opportunity.
Key entities
- CompanyBoston Scientific
Medical device manufacturer (ticker BSX).
